Lead Product(s) : ISA104
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patient with Chronic Hepatitis B Dosed with ISA104 in First-in-Human Phase 1 Study
Details : ISA104 is designed to developed using Synthetic Long Peptide (SLP®) technology and create a strong and specific immune response against HBV, with the aim to functionally cure chronically infected patients.
Product Name : ISA104
Product Type : Vaccine
Upfront Cash : Inapplicable
August 31, 2023
Lead Product(s) : ISA104
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nanovac
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Dutch Leiden University Medical Center
Deal Size : Undisclosed
Deal Type : Partnership
Details : This new vaccine, NANOVAC, is based on microscopic soluble nano-spheres, containing synthetic mini proteins that, when administered as a nasal spray, directly protects the upper respiratory tract including nasal passages and throat (mucosa) before the vi...
Product Name : Nanovac
Product Type : Vaccine
Upfront Cash : Undisclosed
May 01, 2022
Lead Product(s) : Nanovac
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Dutch Leiden University Medical Center
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : ChAdOx1 nCoV-19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : University’S Jenner Institute
Deal Size : Undisclosed
Deal Type : Collaboration
HALIX Enters Collaboration with the University of Oxford for GMP Manufacturing of a COVID-19 Vaccine
Details : Under the collaboration, Halix will utilise its brand new state-of-the-art GMP facilities with capacity up to 1,000 L SUB scale, supporting the manufacture of ChAdOx1 nCoV-19 clinical trial material.
Product Name : AZD1222
Product Type : Vaccine
Upfront Cash : Undisclosed
April 15, 2020
Lead Product(s) : ChAdOx1 nCoV-19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : University’S Jenner Institute
Deal Size : Undisclosed
Deal Type : Collaboration